Replies to post #139787 on Biotech Values

[genisi]

Investor focus should be centered on who will be first to market in GT1 oral.

I think that even if one of ABT's combos is first, it will not be so for long. Even a similar 3 drugs combo but with a more potent PI that doesn't need boosting as you've noted, will likely be considered a better combo.